Search research articles
Contact Us
Filters
Showing results (71-80 of 280) with videos related to
Page
of 28
Sort By:
Cancers
|
November 14, 2019
The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
Arne Velthaus, Kerstin Cornils, Jan K Hennigs, et al.
Cancers
|
November 27, 2024
Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Martin Schönrock, Piet Sonnemann, Nina Michalowski, et al.
Experimental Hematology
|
September 14, 2016
MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development
Edith Schneider, Anna Staffas, Linda Röhner, et al.
Haematologica
|
October 29, 2017
Chromothripsis is linked to <i>TP53</i> alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
Frank G Rücker, Anna Dolnik, Tamara J Blätte, et al.
European Journal of Haematology
|
August 26, 2019
Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation
Daniele Mannina, Nico Gagelmann, Anita Badbaran, et al.
BMC Genomics
|
September 13, 2014
Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
Simone Feurstein, Frank G Rücker, Lars Bullinger, et al.
Oncotarget
|
November 2, 2017
Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy
Min Yang, Zengkai Pan, Kezhi Huang, et al.
Viruses
|
August 10, 2021
Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
Michael A Morgan, Arnold Kloos, Daniela Lenz, et al.
Frontiers in Immunology
|
October 23, 2018
Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Frontiers in Immunology
|
September 26, 2017
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Page
of 28
Search research articles
Search
Showing results (71-80 of 280) with videos related to
Sort By:
Page
of 28
Cancers
|
November 14, 2019
The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
Arne Velthaus, Kerstin Cornils, Jan K Hennigs, et al.
Cancers
|
November 27, 2024
Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Martin Schönrock, Piet Sonnemann, Nina Michalowski, et al.
Experimental Hematology
|
September 14, 2016
MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development
Edith Schneider, Anna Staffas, Linda Röhner, et al.
Haematologica
|
October 29, 2017
Chromothripsis is linked to <i>TP53</i> alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype
Frank G Rücker, Anna Dolnik, Tamara J Blätte, et al.
European Journal of Haematology
|
August 26, 2019
Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation
Daniele Mannina, Nico Gagelmann, Anita Badbaran, et al.
BMC Genomics
|
September 13, 2014
Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
Simone Feurstein, Frank G Rücker, Lars Bullinger, et al.
Oncotarget
|
November 2, 2017
Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy
Min Yang, Zengkai Pan, Kezhi Huang, et al.
Viruses
|
August 10, 2021
Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
Michael A Morgan, Arnold Kloos, Daniela Lenz, et al.
Frontiers in Immunology
|
October 23, 2018
Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Frontiers in Immunology
|
September 26, 2017
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Page
of 28